Cell therapy company Immusoft inks $20 mln Series B
Seattle-based Immusoft Corporation, a cell therapy company, has raised $20 million in Series B financing. The investors included Breakout Ventures, Alexandria Venture Investments, RBV Capital, DEFTA Partners and Mesa Verde Venture Partners.
3 January 2019•1 min read
